NEW YORK, NY (February 13, 2024)—Peggy Lillis Foundation (PLF), a nationwide non-profit group advocating for consciousness and training for Clostridioides difficile (C. diff), proclaims the appointment of three new members to be a part of its board of administrators: Paul Feuerstadt, MD, Debbie Trinker, BA, JD and David Shlaes Ph.D., MD.
“We are delighted to welcome Dr. Feuerstadt, Dr. Shlaes and Mrs. Trinker to our board of administrators. They every deliver a wealth of data and a novel perspective to the struggle towards C. diff,” mentioned PLF President Dr. Gerard Honig.
Paul Feuerstadt, MD, joins PLF’s board of administrators, bringing with him a deep medical data of C. difficile an infection and different infections of the small and giant bowel. Dr. Feuerstadt acquired his M.D. from Weill Medical College of Cornell University. From there, he accomplished his internship and residency in Internal Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center. After finishing his Internal Medicine residency, Dr. Feuerstadt joined the Montefiore Medical Center on the Albert Einstein College of Medicine in New York the place he accomplished his Gastroenterology fellowship. Dr. Feuerstadt started with the PACT Gastroenterology Center, a associate of Hartford Healthcare Medical Group, in 2011. His particular pursuits embody C. difficile an infection and different infections of the small and giant bowel, fecal microbiota transplantation (FMT), ischemic illnesses of the intestine, and different illnesses of the colon and small bowel, together with Irritable Bowel Syndrome (IBS)
Previous Senior Vice President of Regulatory Affairs at Rexall Sundown, Inc. and Kemin Health, L.C, Debbie Trinker additionally joins the board of administrators at PLF—bringing together with her over 26 years of home, worldwide authorized, and regulatory expertise with FDA-regulated merchandise. These positions included transactional and IP expertise, and submissions to FDA, FTC, USDA and worldwide and state regulatory our bodies on e.g., security, claims substantiation, scientific trial knowledge, labeling, opposed occasions, remembers, inspections and Warning Letters. She has served as an officer and member of the Executive Board and Board of Directors of the Council for Responsible Nutrition and has revealed and made shows in areas of FDA-regulated merchandise. Debbie has a B.A. from Northwestern University and a J.D. from Georgetown University Law Center.
Dr. David Shlaes, Ph.D., MD, has had a 40-year profession in anti-infectives, spanning academia and trade with a long-standing scientific curiosity in antimicrobial resistance. Dr. Shlaes educated in infectious illnesses at Case Western Reserve University in Cleveland. He then joined the school and in the end turned a Professor of Medicine. Dr. Shlaes left academia to change into Vice President for Infectious Diseases at Wyeth Pharmaceuticals in 1996. He was a member of the Forum for Emerging Infections of the National Academy of Sciences for seven years. In 2002, Dr. Shlaes turned Executive Vice President, Research and Development for Idenix, Pharmaceuticals, an organization centered on the invention and growth of antivirals. In 2005, he established a consulting firm. During his profession, he contributed considerably to the invention and growth of tigecycline, avibactam, eravacycline and lefamulin. Dr. Shlaes is the creator of three books specializing in his scientific curiosity and in depth analysis on antimicrobial resistance. Since his retirement from Anti-infectives Consulting, he has authored a weblog—Antibiotics the Perfect Storm—on Substack. Dr. Shlaes will deliver methodical perception into antibiotic coverage areas in his new board member place with PLF.
“We have made nice progress in elevating C. diff consciousness, educating and supporting sufferers, and advocating for higher insurance policies, mentioned PLF Chief Executive Officer Christian John Lillis. “These three new board members deliver new insights and strengths to PLF as we glance towards taking the struggle towards C. diff and drug-resistant infections to the subsequent stage.”
The new additions to PLF’s board of administrators sign the start of one other productive and impactful yr of progress in C. diff training, advocacy and laws. The additions come on the heels of PLF’s most profitable C. diff Awareness Campaign to date. The 2023 “See C. diff” marketing campaign achieved its purpose of reaching 23 million folks with C. diff information and preventative data. Additional milestones reached this yr embody PLF organizing the first-ever FDA patient-led C. diff Listening Session, and the approval of new therapeutics to deal with recurrent C. diff. The three new board members are anticipated to deliver revolutionary concepts for PLF to proceed spreading consciousness and advocacy for C. diff.
Clostridium difficile, also called C. diff, is a Gram-positive, spore-forming bacterium that colonizes the human colon, leading to Clostridium difficile an infection (CDI) For extra data go to www.cdiff.org